T88.3
Malignant hyperthermia due to anesthesia
Clinical Classification Guidelines
Use Additional Code
- code for adverse effect, if applicable, to identify drug (T41.- with fifth or sixth character 5)
Medical Intelligence & Overview
Malignant hyperthermia is a rare but life-threatening condition triggered in some people by specific anesthesia drugs used during surgeries. When affected, individuals experience a sudden increase in body temperature and severe muscle contractions, which can quickly lead to complications if not treated promptly. Recognized under the ICD-10 code T88.3, this condition requires quick medical intervention to prevent serious health outcomes.
Causes & Symptoms
Clinical Causes: Genetic predisposition: A hereditary condition where individuals carry genetic mutations affecting muscle cell reactions. Exposure to certain anesthetic agents: Such as volatile anesthetic gases like halothane, sevoflurane, desflurane, and depolarizing muscle relaxants like succinylcholine. Triggers during surgery: The use of specific anesthesia drugs on genetically susceptible individuals can precipitate malignant hyperthermia episodes.
Key Symptoms: Rapid and extreme rise in body temperature Muscle stiffness or twitching Increased heart rate (tachycardia) Rapid breathing (hyperventilation) Skin flushing or redness Elevated carbon dioxide levels in blood Loss of consciousness if untreated
Diagnostic & Treatment
Diagnosis Path: Diagnosis of malignant hyperthermia is primarily based on clinical signs observed during or after anesthesia administration. Special genetic testing and muscle biopsy with a caffeine-halothane test can confirm susceptibility. Early recognition relies on anesthesiologists and medical teams monitoring symptoms closely during procedures involving anesthesia.
Treatment Protocols: Immediate management focuses on stopping all triggering agents and administering specific treatment to halt the hypermetabolic state. The cornerstone therapy is the administration of dantrolene, a muscle relaxant that alleviates symptoms. Supportive measures include cooling the patient's body, correcting metabolic disturbances, and providing intensive supportive care in a hospital setting. Post-episode, patients often undergo genetic counseling and testing to assess future risks.
Clinical Advice & FAQs
Billing Guidance
Is T88.3 a billable ICD-10 code?
Yes, T88.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report T88.3?
Clinical documentation must specify the nature of Malignant hyperthermia due to anesthesia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference